Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33024
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chin, Kai Sin | - |
dc.contributor.author | Churilov, Leonid | - |
dc.contributor.author | Doré, Vincent | - |
dc.contributor.author | Villemagne, Victor L | - |
dc.contributor.author | Rowe, Christopher C | - |
dc.contributor.author | Yassi, Nawaf | - |
dc.contributor.author | Watson, Rosie | - |
dc.date | 2023 | - |
dc.date.accessioned | 2023-06-07T02:47:18Z | - |
dc.date.available | 2023-06-07T02:47:18Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.citation | The Australian and New Zealand Journal of Psychiatry 2024-02; 58(2) | en_US |
dc.identifier.issn | 1440-1614 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/33024 | - |
dc.description.abstract | Neurofibrillary tangles are present in a proportion of people with dementia with Lewy bodies and may be associated with worse cognition. Recent advances in biomarkers for Alzheimer's disease include second-generation tau positron emission tomography as well as the detection of phosphorylated tau at threonine 181 (p-tau181) in plasma. This study aimed to investigate tau in people with dementia with Lewy bodies using a second-generation tau positron emission tomography tracer as well as plasma p-tau181. Twenty-seven participants (mean age 74.7 ± 5.5) with clinically diagnosed probable dementia with Lewy bodies underwent comprehensive clinical assessment and positron emission tomography imaging (18F-MK6240 and 18F-NAV4694). Plasma p-tau181 levels were measured using Simoa technology. Five dementia with Lewy bodies participants (18.5%) had an abnormal tau positron emission tomography (increased tau uptake in the temporal meta-region-of-interest). Higher plasma p-tau181 concentrations correlated with higher tau deposition in the temporal region (ρ = 0.46, 95% confidence interval = [0.10, 0.72]) and classified abnormal tau positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.95 (95% confidence interval = [0.86, 0.99]). Plasma p-tau181 also correlated positively with cortical amyloid-beta binding (ρ = 0.68, 95% confidence interval = [0.40, 0.84]) and classified abnormal amyloid-beta positron emission tomography in dementia with Lewy bodies with an area under the curve of 0.91 (95% confidence interval = [0.79, 0.99]). There was no association found between tau deposition and any of the clinical variables. Tau is a common co-pathology in dementia with Lewy bodies. Plasma p-tau181 correlated with abnormal tau and amyloid-beta positron emission tomography and may potentially be used as a marker to identify co-morbid Alzheimer's disease-related pathology in dementia with Lewy bodies. The clinical implications of tau in dementia with Lewy bodies need to be further evaluated in larger longitudinal studies. | en_US |
dc.language.iso | eng | - |
dc.subject | Alzheimer’s disease | en_US |
dc.subject | Tau | en_US |
dc.subject | dementia with Lewy bodies | en_US |
dc.subject | phosphorylated tau | en_US |
dc.subject | positron emission tomography | en_US |
dc.title | Tau in dementia with Lewy bodies. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | The Australian and New Zealand Journal of Psychiatry | en_US |
dc.identifier.affiliation | Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia | en_US |
dc.identifier.affiliation | Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia. | en_US |
dc.identifier.affiliation | Molecular Imaging and Therapy | en_US |
dc.identifier.affiliation | Medicine (University of Melbourne) | en_US |
dc.identifier.affiliation | Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia | en_US |
dc.identifier.affiliation | Department of Aged Care, The Royal Melbourne Hospital, Parkville, VIC, Australia | en_US |
dc.identifier.affiliation | Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Clayton South, VIC, Australia | en_US |
dc.identifier.affiliation | Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. | en_US |
dc.identifier.doi | 10.1177/00048674231177219 | en_US |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0002-3384-3499 | en_US |
dc.identifier.pubmedid | 37264610 | - |
dc.description.startpage | 48674231177219 | - |
local.name.researcher | Churilov, Leonid | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | The Florey Institute of Neuroscience and Mental Health | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.